Hematopoietic progenitor cell mobilization in mice by sustained delivery of granulocyte colony-stimulating factor.
暂无分享,去创建一个
J. Talmadge | G. Rosenthal | R. Mosley | V. Pisarev | Hongxun Sang | J. Blonder | S. Robinson | J. Chavez
[1] R. Saccardi,et al. Endogenous splenic colonies and megakaryopoiesis in methylcellulose treated irradiated mice , 1985, Experientia.
[2] Y. Sugiyama,et al. Renal Clearance of a Recombinant Granulocyte Colony-Stimulating Factor, Nartograstim, in Rats , 1995, Pharmaceutical Research.
[3] D. Follmann,et al. G‐CSF‐induced spleen size changes in peripheral blood progenitor cell donors , 2003, Transfusion.
[4] R. Mosley,et al. Delivery of Flt3 ligand (Flt3L) using a poloxamer-based formulation increases biological activity in mice , 2003, Bone Marrow Transplantation.
[5] L. R. Hill,et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Kotsilkova,et al. Influence of hydrogel structure on the processes of water penetration and drug release from mixed hydroxypropylmethyl cellulose/thermally pregelatinized waxy maize starch hydrophilic matrices. , 2001, International journal of pharmaceutics.
[7] B. Lord,et al. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] J. Schwartz,et al. The Effect of Formulation Composition and Dissolution Parameters on the Gel Strength of Controlled Release Hydrogel Tablets , 2001, Pharmaceutical development and technology.
[9] S M Moghimi,et al. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. , 2000, Trends in biotechnology.
[10] J. Crawford,et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Metcalf,et al. Identification of a genetic locus modulating splenomegaly induced by granulocyte colony-stimulating factor in mice , 2000, Leukemia.
[12] T. Ulich,et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. , 1999, Experimental hematology.
[13] J. Talmadge,et al. Endogenous interleukin-8 (IL-8) surge in granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization. , 1999, Blood.
[14] F. Aversa,et al. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor , 1999, The Lancet.
[15] I. Benet,et al. Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation , 1998, Bone Marrow Transplantation.
[16] K. Matsushima,et al. Enhanced mobilization of hematopoietic progenitor cells by mouse MIP‐2 and granulocyte colony‐stimulating factor in mice , 1997, Journal of leukocyte biology.
[17] C. Scott,et al. Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. , 1997, Blood.
[18] A. Banga,et al. Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses. , 1997, Pharmaceutical development and technology.
[19] R. Bhardwaj,et al. Controlled‐release delivery system for the α‐MSH analog Melanotan‐I using poloxamer 407 , 1996 .
[20] T. Tötterman,et al. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. , 1996, Bone marrow transplantation.
[21] G. Matsuzaki,et al. Kinetics of serum granulocyte-colony stimulating factor (G-CSF) concentration and G-CSF receptor expression during G-CSF treatment of cyclophosphamide-treated mice. , 1996, International journal of immunopharmacology.
[22] M. Fukuda,et al. Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts , 1996, Antimicrobial agents and chemotherapy.
[23] A. Roberts,et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. , 1995, Blood.
[24] R. Willemze,et al. Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. , 1995, Blood.
[25] D. F. Ward,et al. Intravenous Pluronic F-127 in early burn wound treatment in rats. , 1993, Burns : journal of the International Society for Burn Injuries.
[26] S. Davis,et al. The polyoxyethylene/polyoxypropylene block co‐polymer Poloxamer‐407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow , 1992, FEBS letters.
[27] W. Evans,et al. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. , 1992, Blood.
[28] H. Tanaka,et al. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. , 1991, Cancer research.
[29] H. Tanaka,et al. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor in the rat. Single and multiple dosing studies. , 1991, Drug metabolism and disposition: the biological fate of chemicals.
[30] M. Morimoto,et al. In vitro and in vivo hematopoietic effect of mutant human granulocyte colony-stimulating factor. , 1990, Blood.
[31] T. Dexter,et al. A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony-stimulating factor. , 1990, Blood.
[32] George Morstyn,et al. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor , 1989 .
[33] J. Talmadge,et al. Protective, restorative, and therapeutic properties of recombinant colony-stimulating factors. , 1989, Blood.
[34] S. Davis,et al. Targeting of colloidal particles to the bone marrow. , 1987, Life sciences.
[35] F. Okada,et al. Enhancement of therapeutic effects of recombinant interleukin 2 on a transplantable rat fibrosarcoma by the use of a sustained release vehicle, pluronic gel. , 1987, Cancer research.
[36] D. Boggs,et al. Effect of methylcellulose injection on murine hematopoiesis. , 1977, The American journal of physiology.
[37] I. R. Schmolka. Artificial skin. I. Preparation and properties of pluronic F-127 gels for treatment of burns. , 1972, Journal of biomedical materials research.